Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab The prognostic model demonstrated ...
Researchers conducted a systematic review to assess the risk of bias and applicability of prediction models for fear of recurrence in patients with cancer.